GB791644A - Barbiturate pharmaceutical preparations - Google Patents
Barbiturate pharmaceutical preparationsInfo
- Publication number
- GB791644A GB791644A GB11235/56A GB1123556A GB791644A GB 791644 A GB791644 A GB 791644A GB 11235/56 A GB11235/56 A GB 11235/56A GB 1123556 A GB1123556 A GB 1123556A GB 791644 A GB791644 A GB 791644A
- Authority
- GB
- United Kingdom
- Prior art keywords
- barbiturate
- glutarimide
- sodium
- phenobarbitone
- methyl ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical preparation, which may take the form of tablets, capsules or elixirs, comprises a medicinal barbiturate and a proportion of b ,b -methyl ethyl glutarimide insufficient to interfere with a therapeutic dose of barbiturate but sufficient to overcome the toxic effects of overdose. The glutarimide is present in the proportion of 5 to 30 per cent by weight of the barbiturate. Examples of suitable barbiturates are phenobarbitone, amylobarbitone, butobarbitone, pentobarbitone sodium, quinalbarbitone sodium or hexobarbitone sodium, and when a long acting barbiturate such as phenobarbitone is used the preparation may embody an agent that will delay the release of the b ,b -methyl ethyl glutarimide in the gastro-intestinal tract, such an agent may be cellulose acetate phthalate. Clinical trials with animals and humans using barbiturate dosages of from 15 to 100 mgm. show no significant difference in the sleeping times whether b ,b -methyl ethyl glutarimide is present or not, but in trials using dosages of barbiturates that normally produce a coma lasting 30 to 36 hours, e.g. 2 gms. of phenobarbitone or 1.3 gms. of pentobarbitone, the sleeping time was reduced to about 6 to 8 hours and vital body functions such as blood pressure were not seriously depressed, if 15 to 20 per cent by weight of the glutarimide was contained in the preparations administered. The preparations may also contain stimulants such as caffeine or amphetamine, mild sedatives such as sodium bromide, hypnotics such as chloral or paraldehyde, analgesics such as aspirin, phenacetin or codeine, antiasthamatics such as ephedrine, anticholinergics such as atropine, or anticonvulsants such as hydantoins.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU791644X | 1955-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB791644A true GB791644A (en) | 1958-03-05 |
Family
ID=3758886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB11235/56A Expired GB791644A (en) | 1955-04-20 | 1956-04-12 | Barbiturate pharmaceutical preparations |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB791644A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
US6458384B2 (en) | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
US7682634B2 (en) | 2006-06-19 | 2010-03-23 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US8685443B2 (en) | 2002-09-20 | 2014-04-01 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
-
1956
- 1956-04-12 GB GB11235/56A patent/GB791644A/en not_active Expired
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
US6458384B2 (en) | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
US8685443B2 (en) | 2002-09-20 | 2014-04-01 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
US8685444B2 (en) | 2002-09-20 | 2014-04-01 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
US7682634B2 (en) | 2006-06-19 | 2010-03-23 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
US7682633B2 (en) | 2006-06-19 | 2010-03-23 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8158156B2 (en) | 2006-06-19 | 2012-04-17 | Alpharma Pharmaceuticals, Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
US8846104B2 (en) | 2006-06-19 | 2014-09-30 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
US8877247B2 (en) | 2006-06-19 | 2014-11-04 | Alpharma Pharmaceuticals Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS57212114A (en) | Capsule containing allergen activator and preparation therefor | |
KR850700109A (en) | Antidiuretic DDAVP and its preparation method | |
US4049803A (en) | Augmentation of blood levels of aspirin | |
NO865195L (en) | PROCEDURE FOR THE MANUFACTURE OF A RETARD PREPARATION OF IBUPROFEN. | |
GB791644A (en) | Barbiturate pharmaceutical preparations | |
US2853418A (en) | Hypnotic composition comprising a barbiturate and beta, beta-methyl ethyl glutarimide | |
GB808269A (en) | Barbiturate pharmaceutical preparations | |
GB1302266A (en) | ||
GB1126153A (en) | Novel polygalacturonic acid derivative | |
GB785262A (en) | Improvements in or relating to hypotensive and sedative preparations | |
GB950162A (en) | Medicines for the treatment of hepatic disorders | |
US4120958A (en) | Novel 2-acetoxybenzoic acid-nicotinamide complexes | |
US2726984A (en) | Composition for combatting amoebiasis comprising 1:2-bis(4'-arsono-phenylamino)-ethane | |
GB1110397A (en) | Ephedrine composition | |
GB1292496A (en) | Dosage units of contraceptive preparations for human use | |
GB997914A (en) | Pharmaceutical compositions | |
KR830008678A (en) | Analgesic composition | |
US2793157A (en) | Anticonvulsant 3-ethyl-5-phenyl hydantoin unit dosages and method of using same | |
GB1300486A (en) | Compositions for the treatment of respiratory ailments in man | |
GB1138154A (en) | Improvements in and relating to safeguarding composition containing physiologically active ingredient | |
GB1153014A (en) | Improvements in or relating to An Oral Dose for the Treatment of Tuberculosis | |
Munday et al. | Multiple dose in vivo evaluation of an oral controlled release capsule of theophylline containing film coated mini-tablets in beagle dogs | |
JPS57179118A (en) | Antitumor agent | |
JPS6438027A (en) | Remedy for cancer | |
Tallarida et al. | Phenaphen®/Codeine (Robins) Acetaminophen: Codeine phosphate |